Latterell Venture Partners

Ken Widder

 

 

Ken is an M.D. with over 30 years of experience working with biomedical companies. He has founded seven companies and was Chairman/CEO of six of these. He currently is a General Partner at Latterell Venture Partners and before that, was a General Partner at Windamere Venture Partners.

 

His last company, Sytera Inc. merged with Sirion Therapeutics, an ophthalmology specialty pharmaceutical company.  Prior to Sytera, Ken was a founder and CEO of NovaCardia, a company acquired by Merck after positive phase 2 data.  Prior to NovaCardia, Ken was a founder, Chairman, and CEO of Santarus (NASDAQ:SNTS), which recently was acquired by Salix Pharmaceuticals. Additionally he was Chairman and CEO of Converge Medical, a medical device company developing a sutureless anastamosis system for vein grafts in coronary artery by-pass surgery.

 

Ken started his career as a founder, Chairman and CEO of Molecular Biosystems, where he was responsible for the development and approval of AlbunexTM and Optison TM, the first two ultrasound contrast agents to be approved in the U.S. He currently is responsible for and sits on the boards of Evoke Pharma, Meritage Pharma, and Naurex, Inc. 

 

Ken holds an M.D. from Northwestern University and trained in pathology at Duke University. He is an inventor on over 30 patents and patent applications and has authored or co-authored over 25 publications.

 

 

Copyright © 2016 by Latterell Venture Partners

LVP is Registered in the US Patent and Trademark Office